Format

Send to

Choose Destination
Ann Surg Oncol. 2019 Sep 30. doi: 10.1245/s10434-019-07452-2. [Epub ahead of print]

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.

Author information

1
Department of Surgical Sciences, Akademiska sjukhuset, Uppsala University, Uppsala, Sweden. Wilhelm.graf@surgsci.uu.se.
2
Department of Surgical Sciences, Akademiska sjukhuset, Uppsala University, Uppsala, Sweden.
3
Department of Immunology, Genetics and Pathology, Clinical and Experimental Pathology, Akademiska sjukhuset, Uppsala University, Uppsala, Sweden.

Abstract

BACKGROUND:

KRAS and BRAF mutations are prognostic and predictive tools in metastatic colorectal cancer, but little is known about their prognostic value in patients scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Therefore, we analyzed the prognostic impact of KRAS and BRAF mutations in patients with peritoneal metastases scheduled for CRS and HIPEC.

PATIENTS AND METHODS:

In a consecutive series of 399 patients scheduled for CRS and HIPEC between 2009 and 2017, 111 subjects with peritoneal metastases from primaries of the appendix, colon, or rectum were analyzed for KRAS mutation and 92 for BRAF mutation.

RESULTS:

Mutation in KRAS was present in 51/111 (46%), and mutated BRAF was found in 10/92 (11%). There was no difference in overall survival between KRAS mutation tumors and KRAS wild type, whereas BRAF mutation was associated with short survival. No subject with BRAF mutation survived 2 years. On multivariate analysis, completeness of cytoreduction score (CCS, p = 0.000001), presence of signet cell differentiation (p = 0.000001), and BRAF mutation (p = 0.0021) were linked with poor prognosis.

CONCLUSIONS:

BRAF mutation is a marker of poor prognosis in patients with appendiceal and colorectal peritoneal metastases scheduled for CRS and HIPEC, whereas survival outcome in subjects with mutated KRAS does not differ from wild-type KRAS. This finding suggests that those with BRAF mutation should be considered for alternative treatment options.

PMID:
31571052
DOI:
10.1245/s10434-019-07452-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center